News: Portfolio 2009

Logical Therapeutics Appoints Peter A. Lankau as CEO and Director; Announces Positive Top Line Results of its Clinical Study of LT-NS001 vs. naproxen and Achievement of Financing Milestone

Logical Therapeutics Appoints Peter A. Lankau as CEO and Director

Announces Positive Top Line Results of its Clinical Study of LT-NS001 vs. naproxen and Achievement of Financing Milestone

WALTHAM, MA, May 11, 2009 - Logical Therapeutics, Inc (Logical), a biotechnology company focused on the development of products that treat diseases associated with inflammation, today announced that Peter A. Lankau has been appointed Chief Executive Officer, and has been elected to the Company's Board of Directors. Mr. Lankau was most recently President and CEO of Endo Pharmaceuticals Inc., a publicly traded specialty pharmaceutical company.

 

"I am excited to be teaming up with such an experienced group of scientists and investors to develop clinically meaningful and novel products